Characterization of GUCA1A-associated dominant cone/cone-rod dystrophy: low prevalence among Japanese patients with inherited retinal dystrophies

Kei Mizobuchi1, Takaaki Hayashi1,2*, Satoshi Katagiri1, Kazutoshi Yoshitake3, Kaoru Fujinami4,5,6, Lizhu Yang4,5, Kazuki Kuniyoshi7, Kei Shinoda8, Shigeki Machida9,10, Mineo Kondo11, Shinji Ueno12, Hiroko Terasaki12, Tomokazu Matsuura13, Kazushige Tsunoda4, Takeshi Iwata3 & Tadashi Nakano1

GUCA1A gene variants are associated with autosomal dominant (AD) cone dystrophy (coD) and cone-rod dystrophy (CORD). GUCA1A-associated AD-COD/CORD has never been reported in the Japanese population. The purpose of this study was to investigate clinical and genetic features of GUCA1A-associated AD-COD/CORD from a large Japanese cohort. We identified 8 variants [c.C50_80del (p.E17VfsX22), c.T124A (p.F42I), c.C204G (p.D68E), c.C238A (p.L80I), c.T295A (p.Y99N), c.A296C (p.Y99S), c.C451T (p.L151F), and c.A551G (p.Q184R)] in 14 families from our whole exome sequencing database composed of 1385 patients with inherited retinal diseases (IRDs) from 1192 families. Three variants (p.Y99N, p.Y99S, and p.L151F), which are located on/around EF-hand domains 3 and 4, were confirmed as “pathogenic”, whereas the other five variants, which did not co-segregate with IRDs, were considered “non-pathogenic”. Ophthalmic findings of 9 patients from 3 families with the pathogenic variants showed central visual impairment from early to middle-age onset and progressive macular atrophy. Electroretinography revealed severely decreased or non-recordable cone responses, whereas rod responses were highly variable, ranging from nearly normal to non-recordable. Our results indicate that the three pathogenic variants, two of which were novel, underlie AD-COD/CORD with progressive retinal atrophy, and the prevalence (0.25%, 3/1192 families) of GUCA1A-associated IRDs may be low among Japanese patients.

The guanylate cyclase activator 1A (GUCA1A) gene (OMIM *600364) encodes for guanylyl cyclase-activating protein 1 (GCAP-1), which is expressed in both rod and cone outer segments and regulates synthesis of cGMP from GTP via retinal guanylate cyclase (RetGC) encoded by the retinal guanylate cyclase 2D (GUCY2D) gene. GCAP-1 has four EF-hand domains, three (EF-2, EF-3, and EF-4) of which exhibit Ca2+/Mg2+ binding and act

1Department of Ophthalmology, The Jikei University School of Medicine, Tokyo, Japan. 2Department of Ophthalmology, Katsushika Medical Center, The Jikei University School of Medicine, Tokyo, Japan. 3Division of Molecular and Cellular Biology, National Institute of Sensory Organs, National Tokyo Medical Center, Tokyo, Japan. 4Division of Vision Research, National Institute of Sensory Organs, National Hospital Organization Tokyo Medical Center, Tokyo, Japan. 5Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan. 6UCL Institute of Ophthalmology associated with Moorfields Eye Hospital, London, UK. 7Department of Ophthalmology, Kindai University Faculty of Medicine, Osaka, Japan. 8Department of Ophthalmology, Teikyo University School of Medicine, Tokyo, Japan. 9Department of Ophthalmology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan. 10Department of Ophthalmology, Iwate Medical University School of Medicine, Iwate, Japan. 11Department of Ophthalmology, Mie University Graduate School of Medicine, Mie, Japan. 12Department of Ophthalmology, Nagoya University Graduate School of Medicine, Aichi, Japan. 13Department of Laboratory Medicine, The Jikei University School of Medicine, Tokyo, Japan. *email: taka@jikei.ac.jp
as Ca\(^{2+}/\text{Mg}^{2+}\) sensor proteins\(^{1-6}\). Each EF-hand domain (EF-2, EF-3, and EF-4) consists of a helix-loop-helix secondary structure that is able to chelate Ca\(^{2+}\), whereas EF-1 domain serves as a target-binding domain. In the dark-adapted state, when cytosolic Ca\(^{2+}\) concentration is high, GCAP-1 binds Ca\(^{2+}\) and inhibits RetGC activity and cGMP synthesis. cGMP is hydrolyzed by light-activated phosphodiesterase in the light-adapted state, leading to closure of cation channels and low cytosolic Ca\(^{2+}\) concentration\(^{7,8}\) in which GCAP-1 releases Ca\(^{2+}\). Then, Mg\(^{2+}\) binds to the EF-2 and/or EF-3 in the Ca\(^{2+}\)-free state of GCAP-1, and the Mg\(^{2+}\)-bound GCAP-1 activates RetGC. Interestingly, mutated GCAP-1 (e.g. p.Y99C, p.D100E, p.L151F) associated with disease-causing GUCA1A variants show persistently stimulated RetGC activity, leading to the elevation of cytosolic Ca\(^{2+}\) and cGMP concentrations and resulting in initiation of photoreceptor cell death\(^9-13\).

Heterozygous GUCA1A variants have been reported as causes of autosomal dominant (AD) maculodystrophy (MD), cone dystrophy (COD), and cone-rod dystrophy (CORD)\(^{9,14-16}\). Previous studies have revealed that most patients with GUCA1A variants finally exhibit a CORD phenotype with progressive macular atrophy\(^ {9,14,15,19,20}\). To date, all reported GUCA1A variants are missense or in-frame insertion/deletion types, according to the Human Gene Mutation Database (HGMD, http://www.hgmd.cf.ac.uk/). A large US cohort study of inherited retinal dystrophies (IRDs) has revealed the prevalence of GUCA1A-associated IRD is 0.7% (7/1000 families)\(^{21}\). However, to our knowledge, IRDs associated with GUCA1A variants have never been reported in the Japanese population\(^{22}\).

In this study, we identified rare GUCA1A variants from our whole exome sequencing (WES) database composed of IRD patients from a large Japanese cohort. The purpose of this study was to investigate the pathogenicity of rare GUCA1A variants and clinical and genetic features of GUCA1A-associated IRDs.

**Results**

**Genetic analysis.** We identified eight rare GUCA1A variants [c.C50_80del (p.E17VfsX22), c.T124A (p.F42I), c.C204G (p.D68E), c.C238A (p.L80I), c.T295A (p.Y99N), c.A296C (p.Y99S), c.C451T (p.L151F), and c.A551G (p.Q184R)] from 14 unrelated families after filtering (Supplementary Table S1). According to the American College of Medical Genetics and Genomics (ACMG) criteria, three variants (p.Y99N, p.Y99S, and p.L151F) from three families (NTMC 244, IKEI 136, and IKEI 215) were confirmed as "pathogenic" (Fig. 1A, B). Two (p.Y99N and p.Y99S) of the 3 variants were novel, while the remaining variant (p.L151F) was previously reported as the cause of AD-CORD\(^ {16,19}\). The 3 variants co-segregated with the disease and were located on around EF-hand domain 3 and 4, which is essential for cytosolic Ca\(^{2+}/\text{Mg}^{2+}\) binding (Fig. 1C).

**Clinical study.** In 3 families with the pathogenic GUCA1A variants (p.Y99S, p.Y99N, and p.L151F), a total of 9 affected patients were clinically investigated (Fig. 1A). The examined age ranged from 15 to 69 years old (mean age: 43.0 years, standard deviation: 18.3 years). Clinical findings of the 9 affected patients are summarized in Table 1.

**Onset, initial symptoms, and visual acuity.** The age of onset ranged from 3 to 30 years old (mean age: 14.6 years, standard deviation: 9.6 years). Initial symptoms were available from 9 patients and included reduced visual acuity (9/9, 100%), photophobia (3/9, 33.3%), and central visual field loss (1/9; 11.1%). The decimal best-corrected visual acuity of the nine patients ranged from 0.01 to 0.8 at the examined age (Table 1).

**Fundus photographs, FAF, and OCT findings.** Each examination showed variable degrees of retinal abnormalities (Fig. 2) and we classified the abnormalities into early, middle, and advanced stages according to the severity of macular atrophy. Patient F2: III-1 was classified into early stage and exhibited discoloration and slight hyper-autofluorescence limited at the fovea in fundus and FAF images and preserved hyper-reflectivity of the ellipsoid zone (EZ) with the foveal bulge in OCT images. Two patients (F3: II-1 and F3: II-2) were classified into middle stage and exhibited almost normal fundus appearance or slight macular atrophy in fundus photographs, hyper-autofluorescent ring around the fovea in FAF images, and diffusely decreased or disrupted EZ without the foveal bulge in OCT images. Patient F2: II-1 was also classified into middle stage and exhibited macular atrophy in fundus photographs, hypo-autofluorescent area corresponding to retinal atrophy with hyper-autofluorescence around the area in FAF images, and diffusely decreased or disrupted EZ without the foveal bulge in OCT images. Five patients (F1: II-1, F1: I-2, F2: II-2, F2: I-1, and F3: I-1) were classified into advanced stage and exhibited retinal atrophy at the macula or posterior pole in fundus photographs, loss of autofluorescent area corresponding to retinal atrophy with hyper-autofluorescence around the area in FAF images, and disrupted EZ and thinning of the outer retina corresponding to the retinal atrophic area with hypo-reflectivity of the EZ outside the area in OCT images. The atrophic areas were apparently more enlarged in older patients (i.e., 15-year-old patient F2: III-1 at the early stage, mean age of 33.3 years in the middle stage, and mean age of 54.4 years in the advanced stage). In addition, the enlargement pattern of the atrophic area was different between family 1 and the other 2 families. Retinal atrophy in family 1 extended over the optic disc and inferior arcade whereas that in families 2 and 3 showed elliptical enlargement within the vascular arcade.
Visual field findings. The results of visual field testing were obtained from 14 eyes of 7 patients. All 7 patients exhibited central visual field loss corresponding to retinal abnormalities. Patient F2: III-1 with early stage abnormality showed normal visual field in the right eye and slightly decreased central sensitivity in the left eye in HFA.
The six patients were examined using GP. Two patients with middle stage abnormalities showed central scotoma of V-4e isopter in the right eye (F3: II-2) and central scotoma of I-4e isopter in three eyes (both eyes of F3: II-1 and the left eye of F3: II-2). One patient with middle stage abnormality and two patients with advanced stage abnormalities showed central scotoma of V-4e isopter in all eyes (F2: II-1, F1: II-2, and F2: II-2), and one patient with advanced stage abnormality showed central visual field loss in both eyes (F1: I-2). The areas of central scotomas were consistent with the lesions of retinal atrophy.

Four (F1: II-2, F2: II-2, F3: II-1, and F3: II-2) of 5 patients, whose retinal atrophy was limited to the posterior pole, showed preserved peripheral visual fields. In contrast, patients F2: II-1 and F1: I-2 exhibited constriction of the peripheral visual field and an island limited to the inferior area.

Full-field electroretinographic findings. Full-field (FF)-electroretinography (ERG) recording was performed in 16 eyes of 8 patients. The results showed severely decreased or non-recordable cone responses in all patients (Fig. 3). Regarding rod responses, three patients (F2: III-1, F3: II-1, and F3: II-2) with early to middle stage abnormalities exhibited preserved rod responses, whereas 5 patients (F1: I-2, F1: II-2, F2: II-2, F2: II-1, and F3: I-1) with advanced stage abnormalities exhibited decreased and non-recordable rod responses, respectively (Fig. 3).

Discussion

In this study, eight rare GUCA1A variants, three of which were pathogenic, were identified in our large Japanese cohort. Furthermore, we demonstrated clinical features of nine COD/CORD patients from three unrelated Japanese families with two novel variants (p.Y99S and p.Y99N) and one known variant (p.L151F).

To date, 19 GUCA1A missense and 3 in-frame deletion/insertion variants in heterozygous states have been reported as causes of AD-MD and AD-COD/CORD in HGMD Professional (2019.3),24-18,20,23-33. Most reported variants (18/22, 81.8%) were concentrated within or around EF-hand domains 3 and 4, which are essential for cytosolic Ca$^{2+}$/Mg$^{2+}$ binding.4-6 Amino acid residues Y99 and L151 are also located on EF-hand 3 helix E and EF-hand 4 loop, respectively (Fig. 1C). Regarding the two novel variants (p.Y99S and p.Y99N), a different variant (p.Y99C) at the same position has been reported as “pathogenic” and leads to COD/CORD.4,19 The variant p.L151F has also been reported as a cause of CORD.16,19 In contrast, the other five variants (p.E17VfsX22, p.F42I, p.D68E, p.L80I, and p.Q184R) identified in the present study, which resulted in uncertain significance in the ACMG criteria, did not co-segregate with the disease. Previously, only five missense variants (p.L50I, p.L84F, p.G86R, p.E89K, and p.L176F) located outside EF-hand domains 3 and 4 have been reported as “pathogenic”14,15,18,23,33 and one variant (p.L50I) has been concluded as “non-pathogenic” by subsequent studies35,36. Experimental studies have clarified that most GUCA1A variants within or around EF-hand domains 3 and 4 lead to the constitutive activation of RetGC by mechanisms of either a dominant-negative effect or gain of function, not haploinsufficiency9,19,23,27,30,31,36. While, recent studies have also demonstrated that the mutated GCAP-1 (p.L84F and p.L176F), located outside EF-hand domains 3 and 4, showed a significantly high affinity for Mg$^{2+}$ by altered tertiary structure or conformational changes, resulting in stabilizing the RetGC-activating state.36,37 Certainly, all reported GUCA1A variants are heterozygous missense or in-frame insertion/deletion variants, but not truncated variants, compatible with the mechanisms of dominant-negative effect/gain of function. Regarding the reported p.Y99C variant44, the mutated GCAP-1 disrupts the N-terminal helix of the helix-loop-helix conformation of the EF-hand domain 3, severely affecting Ca$^{2+}$ binding at the site3,10. Further, the p.Y99C mutant activates RetGC at low Ca$^{2+}$ concentration, similar to wild-type GCAP-1, but remains active even at high Ca$^{2+}$ concentration, when wild-type GCAP-1 normally inhibits the target9,13,14. A similar pathomechanism whereby RetGC activity cannot be suppressed even at high cytosol Ca$^{2+}$ concentration may be considered to be CORD caused by our novel variants (p.Y99N and p.Y99S). While it is demonstrated that the p.L151F mutant showed decreased Ca$^{2+}$ affinity and significantly lower thermal stability compared to the wild-type protein4,16. Among the five non-pathogenic GUCA1A variants identified in this study, p.E17VfsX22, a truncated variant, might be considered to be a haploinsufficiency mechanism, whereas the other four missense variants were located outside EF-hand domains 3 or 4. However, we did not perform any biochemical or biophysical experiment using the four missense mutants (p.F42I, p.D68E, p.L80I, and p.Q184R). Further, complex pathogenic mechanisms have been reported about mutated GCAP-1 outside EF-hand domains 3 and 4.18,36,37 Although functional influence by the mutated GCAP-1 was not determined experimentally, all five GUCA1A variants (p.E17VfsX22, p.F42I, p.D68E, p.L80I, and p.Q184R) did not cosegregate with the disease; some family members with the variants were unaffected, concluding that the 5 variants were non-pathogenic.

All reported GUCA1A-associated phenotypes are classified into AD-MD or AD-COD/CORD with progressive macular atrophy.14,15,19,23,25,32 In our study, the retinal atrophic areas were apparently more enlarged in older patients. In regard to cone ERG, although previous studies have shown that a variable degree of responses is seen ranging from preserved cone responses in AD-MD to severely decreased cone responses in AD-COD/CORD.14,25,25,32,35, all 8 patients examined exhibited severely decreased or non-recordable cone responses (Fig. 3). In contrast, the findings of rod ERG showed a variable degree of responses ranging from normal to non-recordable (Fig. 3), consistent with data from previous studies14,15,19,23,25,30,31,36. It is unclear why cone photoreceptors are initially and predominantly affected in AD-MD and AD-COD/CORD in which wild-type versus mutated GCAP-1 might function at different ratios between cone and rod photoreceptors. Taken together, retinal...
| Family ID, patient ID, Unique ID, age of onset, examined age, gender | Initial symptoms | BCVA (decimal) | Fundus photographs | Fundus autofluorescence imaging | Optical coherence tomography | Visual field testing (Goldmann perimeter) | Full-field electroretinogram | GUCA1A variant |
|---|---|---|---|---|---|---|---|---|
| 1, II-2, JU0330, 3, 40, M | Reduced visual acuity | 0.2 0.2 | Advanced stage | Extention of the retinal atrophy in direction to the optic disc and inferior arcader vessel | Loss of AF at retinal atrophyp area with hyper-AF around the area | Disrupted | Present | Absolute central scotoma | Rod: decreased b-wave, Combined: normal a-wave and decreased b-wave, Cone and 30-Hz flickers: non-recordable | c.296A > C (p.Y99S) |
| 1, I-2, JU0983, 6, 68, F | Reduced visual acuity | 0.01 0.02 | Advanced stage | Extention of the retinal atrophy over the optic disc and inferior arcader vessel | Loss of AF at retinal atrophy area with hyper-AF around the area | Disrupted | Present | Loss of central visual field | Rod: non-recordable, Combined: non-recordable, Cone and 30-Hz flickers: non-recordable | c.296A > C (p.Y99S) |
| 2, II-1, KA244, 22, 35, F | Photophobia, reduced visual acuity | 0.2 0.1 | Middle stage | Macular atrophy | hypo-AF at retinal atrophy area with hyper-AF around the area | Disrupted/diffused | Absent | Absolute central scotoma | Rod: decreased b-wave, Combined: decreased a and b-waves, Cone and 30-Hz flickers: non-recordable | c.295T > A (p.Y99N) |
| 2, II-2, KA248, 19, 30, M | Photophobia, reduced visual acuity | 0.15 | Advanced stage | Severe macular atrophy | Loss of AF at retinal atrophy area with hyper-AF around the area | Disrupted | Present | Absolute central scotoma | Rod: decreased b-wave, Combined: decreased a and b-waves, Cone and 30-Hz flickers: non-recordable | c.295T > A (p.Y99N) |
| 2, I-1, KA301, 18, 65, M | Reduced visual acuity, central visual field loss | 0.01 0.01 | Advanced stage | Elliptical enlargement of retinal atrophy within the vascular arcades | Loss of AF at retinal atrophy area with hyper-AF around the area | Disrupted | Present | Not done | Not done | c.295T > A (p.Y99N) |
| 2, III-1, KA346, 4, 15, M | Photophobia and reduced visual acuity | 0.7 0.7 | Early stage | Discoloration limited at the fovea | Sligt hyper-AF limited at the fovea | Preserved | Absent | Normal in RE and slightly decreased central sensitivity in LE in HFA | Rod: normal b-wave, Combined: normal a-wave and decreased b-wave, Cone and 30-Hz flickers: severely decreased | c.295T > A (p.Y99N) |
| 3, II-1, JU0843, 30, 34, M | Reduced visual acuity | 0.5 0.8 | Middle stage | Almost normal fundus appearance | Hyper-AF ring around the fovea | Disrupted/diffused | Absent | Relative central scotoma | Rod: normal b-wave, Combined: normal a-wave and decreased b-wave, Cone and 30-Hz flickers: severely decreased | c.451C > T (p.L151F) |
| 3, I-1, JU1258, NI, 69, M | Reduced visual acuity | 0.09 | Advanced stage | Elliptical enlargement of retinal atrophy in direction over optic disc to nasal retina | Loss of AF at retinal atrophy area with hyper-AF around the area | Disrupted | Present | Not done | Rod: decreased b-wave, Combined: decreased a and b-waves, Cone and 30-Hz flickers: non-recordable | c.451C > T (p.L151F) |
| 3, II-2, JU1259, NI, 31, M | Reduced visual acuity | 0.2 0.4 | Middle stage | Slight macular atrophy | Hyper-AF ring around the fovea | Disrupted/diffused | Absent | Absolute central scotoma in RE and relative central scotoma in LE | Rod: normal b-wave, Combined: normal a-wave and decreased b-wave, Cone and 30-Hz flickers: severely decreased | c.451C > T (p.L151F) |

Table 1. Clinical findings of patients with pathogenic variants. AF = autofluorescence, BCVA = best corrected visual acuity, BE = both eyes, DA = dark adaptation, EZ = ellipsoid zone, F = female, HFA = Humphrey Field Analyzer, LA = light adaptation, LE = left eye, NI = no information, M = male, RE = right eye.

 function gradually deteriorates and leads to COD/CORD in patients with heterozygous pathogenic GUCA1A variants. Clinical features of our 9 patients were consistent with previous studies asCORD with progressive macular atrophy; however, the centrifugal extension pattern of retinal atrophy was different between the families (Fig. 2). Unlike elliptical enlargement of retinal atrophy in families 2 and 3 and previous studies, retinal atrophy in family 1 extended over the optic disc and inferior arcade. This unique pattern of retinal atrophy might be a characteristic finding of the p.Y99S variant or be influenced by secondary (genetic or environmental) factors. In addition, the older patient (F1: I-2) with p.Y99S showed non-recordable responses not only in cone ERG but also in rod and combined ERG, and peripheral visual field loss except for the inferior area. To our knowledge, this is the first report of such a case. The clinical course of GUCA1A-associated dystrophies typically exhibits progressive cone dysfunction with macular atrophy, accompanied by later rod dysfunction. Although it is not clarified whether GUCA1A-associated dystrophies ultimately lead to entire loss of rod function in addition to loss of cone function, our finding of patient F1: I-2 suggests that these dystrophies might lead to severe loss of both rod and cone function as the result of continuous progression.
In this study, our cohort of IRDs revealed the prevalence (0.25%, 3/1192 families) of GUCA1A-associated IRDs was lower than that (0.7%, 7/1000 families) of previous large US cohort study. Our study suggests that GUCA1A-associated IRDs in Japanese population may be rarer compared with US population. In fact, any IRDs associated with GUCA1A variants have never been reported in the Japanese population. Further investigations will need to be undertaken in order to clarify the prevalence of GUCA1A-associated IRDs in each population.

Figure 2. Fundus photographs, fundus autofluorescence imaging, and optical coherence tomography images. Each patient showed variable degrees of macular atrophy. Nine patients were classified into three stages (early stage: retinal abnormalities limited at the fovea, middle stage: retinal abnormalities within the macular area and advanced stage: retinal abnormalities beyond the macular area) based on the severity of macular atrophy. One patient (F2: III-1) had early stage abnormality, three patients (F3: II-1, F3: II-2, and F2: II-1) had middle stage abnormalities, and five patients (F1: II-2, F1: I-2, F2: II-2, F2: I-1, and F3: I-1) had advanced stage abnormalities.
In conclusion, we identified eight rare GUCA1A variants including three pathogenic variants from a large Japanese cohort. Our results indicated that the three pathogenic variants underlie AD-COD/CORD with progressive retinal atrophy, and the prevalence of GUCA1A-associated IRDs may be low among Japanese patients with IRDs.

**Patients and Methods**

**Ethics statement.** Institutional Review Boards of the seven participating institutions approved the study protocol [The Jikei University School of Medicine (approval number 24–232 6997); National Hospital Organization Tokyo Medical Center (approval number: R18-029); Nagoya University Graduate School of Medicine (approval number: 2010–1067); Mie University Graduate School of Medicine (approval number: 2429); Teikyo University School of Medicine (approval number: 10-007-4); Iwate Medical University School of Medicine (approval number: HGH23-1); and Kindai University Faculty of Medicine (approval number: 22–132)]. The protocol adhered to the tenets of the Declaration of Helsinki, and informed consent was obtained from each participant before participating in this study.

**Molecular genetic study.** Patients with IRDs were studied from the genotype-phenotype database of the Japan Eye Genetics Consortium (http://www.jegc.org/). We examined our in-house WES database of 1385 IRD patients and 682 of their family members from 1192 Japanese families. In fact, WES with targeted analysis of the IRD genes listed in the RetNet database (https://sph.uth.edu/retnet/home.htm) was performed. The details of the WES methodology are described elsewhere. We selected patients with IRDs who had rare GUCA1A variants in at least in one allele with a frequency of less than 1% in the Human Genetic Variation Database (http://www.hgvd.genome.med.kyoto-u.ac.jp/index.html) and a total frequency of less than 1.0% of the genome Aggregation Database (http://gnomad.broadinstitute.org). Subsequently, the pathogenicity of identified GUCA1A variants was evaluated according to the standards and guidelines of the ACMG. Lastly, we evaluated the damage to GCAP-1 by using three in silico programs [PolyPhen2 (http://genetics.bwh.harvard.edu/pph2/)],

![Figure 3.](image)

**Figure 3.** Full-field electroretinography findings. Full-field electroretinography (FF-ERG) shows severely decreased or non-recordable light-adapted cone and 30-Hz flicker responses in all eight examined patients. Dark-adapted rod and combined rod-cone/flash ERG findings show preserved responses in three patients (F2: III-1, F3: II-1, and F3: III-2), decreased responses in four patients (F1: II-2, F2: II-2, F2: II-1, and F3: I-1), and non-recordable responses in one patient (F1: I-2).
SIFT (http://sift.jcvi.org/www/SIFT_seq_submit2.html), and MutationTaster (http://www.mutationtaster.org/)]. Confirmation and segregation of each GUCA1A variant were performed by Sanger sequencing. Identified GUCA1A variants were compared with the NCBI reference sequence (NM_000409.4).

**Clinical study.** We retrospectively reviewed the detailed medical records of patients with GUCA1A variants, which were determined as pathogenic in genetic analysis. Each patient underwent a comprehensive ophthalmic examination, including decimal best-corrected visual acuity, fundoscopy, fundus autofluorescence imaging (FAF; Spectralis HRA; Heidelberg Engineering, Heidelberg, Germany), optical coherence tomography (OCT; Carl Zeiss Meditec AG, Dublin, CA, USA), and visual field testing using Goldmann perimetry (GP; Haag-Streit, Bern, Switzerland) and/or Humphrey field analyzer (HFA; Carl Zeiss Meditec AG). FF-ERG using a light-emitting diode built-in electrode (LE-4000, Tomey, Nagoya, Japan) was recorded in accordance with the protocols of the International Society for Clinical Electrophysiology of Vision (ISCEV)45 with the exception of using a stronger flash under dark-adapted (DA) conditions to record a DA 200 (200 cd·s·m−2) ERG. Ganzfeld FF-ERG using Neuropack 2 (Nihon Kohden, Tokyo, Japan) with corneal contact lens electrodes was recorded according to the ISCEV protocols except for DA 10.0 (10.0 cd·s·m−2) ERG. The detailed procedure and conditions of FF-ERG were previously reported44,46-48.

Received: 28 August 2019; Accepted: 21 October 2019;
Published online: 14 November 2019

**References**

1. Cuenca, N., Lopez, S., Howes, K. & Kolb, H. The localization of guanylyl cyclase-activating proteins in the mammalian retina. Invest Ophthalmol Vis Sci 39, 1243–1250 (1998).
2. Mendez, A. et al. Role of guanylate cyclase-activating proteins (GCAPs) in setting the flash sensitivity of rod photoreceptors. Proc Natl Acad Sci USA 98, 9948–9953 (2001).
3. Pennesi, M. E., Howes, K. A., Baehr, W. & Wu, S. M. Guanylate cyclase-activating protein (GCAP) 1 rescues cone recovery kinetics in GCAP1/GCAP2 knockout mice. Proc Natl Acad Sci USA 100, 6783–6788 (2003).
4. Palczewski, K. et al. Molecular cloning and characterization of retinal photoreceptor guanylyl cyclase-activating protein. Neuron 13, 395–404 (1994).
5. Gorczyca, W. A. et al. Guanylyl cyclase activating protein. A calcium-sensitive regulator of phototransduction. J Biol Chem 270, 22029–22036 (1995).
6. Peschenko, I. V. & Dizhoor, A. M. Ca2+ and Mg2+ binding properties of GCAP-1. Evidence that Mg2+-bound form is the physiological activator of photoreceptor guanylyl cyclase. J Biol Chem 281, 23830–23841 (2006).
7. Dizhoor, A. M., Lowe, D. G., Olshevskaya, E. V., Laura, R. P. & Hurley, J. B. The human photoreceptor membrane guanylyl cyclase, RetGC, is present in outer segments and is regulated by calcium and a soluble activator. Neuron 12, 1345–1352 (1994).
8. Lowe, D. G. et al. Cloning and expression of a second photoreceptor-specific membrane retina guanylyl cyclase (RetGC), RetGC-2. Proc Natl Acad Sci USA 92, 5535–5539 (1995).
9. Sokal, I. et al. GCAP1 (Y99C) mutant is active in autosomal dominant cone dystrophy. Mol Cell 2, 129–133 (1998).
10. Dizhoor, A. M., Bojko, S. G. & Olshevskaya, E. V. Constitutive activation of photoreceptor guanylate cyclase by Y99C mutant of GCAP-1. Possible role in causing human autosomal dominant cone degeneration. J Biol Chem 273, 17311–17314 (1998).
11. Olshevskaya, E. V. et al. The Y99C mutation in guanylyl cyclase-activating protein 1 increases intracellular Ca2+ and causes photoreceptor degeneration in transgenic mice. J Neurosci 24, 6678–6685 (2004).
12. Jiang, L. & Baehr, W. GCAP1 mutations associated with autosomal dominant cone dystrophy. Adv Exp Med Biol 664, 273–282 (2010).
13. Behnen, P., Delloro, D. & Koch, K. W. Involvement of the calcium sensor GCAP1 in hereditary cone dystrophies. Hum Mol Genet 945–954 (2017).
14. Downes, S. M. Calcium-sensing and perturbed second messenger homeostasis in photoreceptors. Exp Eye Res 109, 1–12 (2012).
15. Carss, K. J. et al. Comprehensive Rare Variant Analysis via Whole-Genome Sequencing to Determine the Molecular Pathology of Inherited Retinal Disease. Am J Hum Genet 100, 75–90 (2017).
16. Taylor, R. L. et al. Panel-Based Clinical Genetic Testing in 85 Children with Inherited Retinal Disease. Ophthalmology 124, 985–991 (2017).
17. Nong, E., Lee, W., Merriam, J. E., Allikmets, R. & Tsang, S. H. Disease progression in autosomal dominant cone-rod dystrophy previously reported41,46–48.
18. Stone, E. M. et al. A novel GCAP1 missense mutation (L151F) in a large family with autosomal dominant cone-rod dystrophy. Mol Vis 19, 143–151 (2013).
19. Sokal, I. et al. A novel GCAP1(N104K) mutation in EF-hand 3 (EF3) linked to autosomal dominant cone dystrophy. Mol Vis 23, 1124–1132 (2017).
30. Nishiguchi, K. M. et al. A novel mutation (I143NT) in guanylate cyclase-activating protein 1 (GCAP1) associated with autosomal dominant cone degeneration. *Invest Ophthalmol Vis Sci* **45**, 3863–3870 (2004).

31. Wilkie, S. E. et al. Identification and functional consequences of a new mutation (E155G) in the gene for GCAP1 that causes autosomal dominant cone dystrophy. *Am J Hum Genet* **69**, 471–480 (2001).

32. Huang, L. et al. Novel GUCA1A mutation identified in a Chinese family with cone-rod dystrophy. *Neurosci Lett* **541**, 179–183 (2013).

33. Weisbuch, N. et al. Mutation Detection in Patients with Retinal Dystrophies Using Targeted Next Generation Sequencing. *PLoS One* **11**, e0145951 (2016).

34. Payne, A. M. et al. A mutation in guanylate cyclase activator 1A (GUCA1A) in an autosomal dominant cone dystrophy pedigree mapping to a new locus on chromosome 6p21.1. *Hum Mol Genet* **7**, 273–277 (1998).

35. Sokal, L. I. et al. Ca(2+) binding proteins in the retina: from discovery to etiology of human disease(1). *Biochim Biophys Acta* **1498**, 233–251 (2000).

36. Marino, V., Scholten, A., Koch, K. W. & Dell’Orco, D. Two retinal dystrophy-associated missense mutations in GCAP1 with distinct molecular properties result in a similar aberrant regulation of the retinal guanylate cyclase. *Hum Mol Genet* **24**, 6653–6666 (2015).

37. Vocke, E. et al. Dysfunction of cGMP signalling in photoreceptors by a macular dystrophy-related mutation in the calcium sensor GCAP1. *Hum Mol Genet* **26**, 133–144 (2017).

38. Dell’Orco, D., Behnen, P., Lim, S. & Koch, K. W. Calcium binding, structural stability and guanylate cyclase activation in GCAP1 variants associated with human cone dystrophy. *Cell Mol Life Sci* **67**, 973–984 (2010).

39. Schmitz, F. et al. EF hand-mediated Ca- and cGMP-signaling in photoreceptor synaptic terminals. *Front Mol Neurosci* **5**, 26 (2012).

40. Dell’Orco, D., Sulmann, S., Ziegel, P., Marino, V. & Koch, K. W. Impact of cone dystrophy-related mutations in GCAP1 on a kinetic model of phototransduction. *Cell Mol Life Sci* **71**, 3829–3840 (2014).

41. Fujimami, K. et al. Novel RPL11 Variants and Genotype-Photoreceptor Microstructural Phenotype Associations in Cohort of Japanese Patients With Occult Macular Dystrophy. *Invest Ophthalmol Vis Sci* **57**, 4837–4846 (2016).

42. Kameya, S. et al. Phenotypical Characteristics of POC1B-Associated Retinopathy in Japanese Cohort: Cone Dystrophy With Normal Fundusoscopic Appearance. *Invest Ophthalmol Vis Sci* **60**, 3432–3446 (2019).

43. Katagiri, S. et al. Compound heterozygous splice site variants in the SLC17 gene highlight an additional candidate locus for Senior-Loken syndrome. *Sci Rep* **8**, 16733 (2018).

44. Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* **17**, 405–424 (2015).

45. McCulloch, D. L. et al. ISCEV Standard for full-field clinical electroretinography (2015 update). *Doc Ophthalmol* **130**, 1–12 (2015).

46. Hayashi, T. et al. Compound heterozygous RDH5 mutations in familial fleck retina with night blindness. *Acta Ophthalmol Scand* **84**, 254–258 (2006).

47. Katagiri, S. et al. RPE65 Mutations in Two Japanese Families with Leber Congenital Amaurosis. *Ophthalmic Genet* **37**, 161–169 (2016).

48. Kutsuna, T. et al. Novel biallelic loss-of-function KCNV2 variants in cone dystrophy with supernormal rod responses. *Doc Ophthalmol* **138**, 229–239 (2019).

**Acknowledgements**

We thank the patients and their families for participation in this study. We thank Ritsuko Nakayama for assistance in genetic analysis. This work was supported by grants from the Practical Research Project for Rare/Intractable Diseases (17ek0109282h0001 to T.I.) from the Japan Agency for Medical Research and Development (AMED), the Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research (17K11434 to T.H.), and Japanese Retinitis Pigmentosa Society (JRP-S) Research Grant (to T.H.).

**Author contributions**

K.M. and T.M. performed the molecular genetic analyses in 3 families with pathogenic GUCA1A variants. K.Y. and T.I. performed the whole-exome sequencing. K.M., S.K. and T.H. interpreted the data and wrote the manuscript. K.F., L.Y., T.M. and T.N. assisted with data interpretation. K.K., K.S., S.M., M.K., S.U., H.T. and K.T. performed ophthalmic examination at each institution. T.H. designed and supervised the study. All authors have read and approved the final manuscript.

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Supplementary information** is available for this paper at [https://doi.org/10.1038/s41598-019-52660-1](https://doi.org/10.1038/s41598-019-52660-1).

**Correspondence** and requests for materials should be addressed to T.H.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

© The Author(s) 2019